Inactive Instrument

Centrexion Therapeutics Corporation

Equities

CNTX

US15643W1009

Biotechnology & Medical Research

Centrexion Corp announced that it has received $69.57 million in funding from a group of investors

January 01, 2018

On January 2, 2018, Centrexion Corp closed the transaction. The company has received series D round of funding from 67 investors. The transaction was led by New Enterprise Associates. The transaction included participation from new and existing investors including, InterWest Partners LLC and other investors, certain investment funds advised by Clough Capital Partners, L.P., ArrowMark Colorado Holdings, LLC, 6 Dimensions Capital, L.P., a fund managed by 6 Dimensions Capital, Quan Capital, and Efung Capital. As part of the transaction, Sara Nayeem of New Enterprise Associates and Stella Xu of Quan Capital have joined the company’s board of directors.

Latest news about Centrexion Therapeutics Corporation

Centrexion Therapeutics Corp. announced a financing transaction	12-27	CI
Centrexion Therapeutics Corporation announced that it has received $2.3 million in funding	11-26	CI
Centrexion Therapeutics Corporation announced that it expects to receive $2.3 million in funding	11-13	CI
Centrexion Therapeutics Corp. announced that it has received $10.280238 million in funding	10/07/23	CI
Centrexion Therapeutics Corporation announced a financing transaction	13/06/23	CI
Centrexion Therapeutics Corporation announced that it has received $29.14 million in funding	10/08/22	CI
Centrexion Therapeutics Corporation announced that it has received $16.475 million in funding	07/06/22	CI
Centrexion Therapeutics Corporation announced that it expects to receive $16.475 million in funding	23/05/22	CI
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Posts Q1 Loss $-0.22	11/05/22	MT
HC Wainwright Starts Context Therapeutics at Buy With $6 Price Target	02/02/22	MT
ThinkEquity Starts Context Therapeutics at Buy with $10 Price Target	24/01/22	MT
Health Care Stocks Staying On Positive Ground in Late Trade	10/12/21	MT
Health Care Stocks Hanging On For Slim Gains	10/12/21	MT
Wall Street Sees Upbeat Open, US CPI Rises More Than Expected	10/12/21	MT
Top Premarket Gainers	10/12/21	MT
Context Therapeutics Says Drug Candidate Decreased Reproduction of Breast Cancer Tumor Cells in Open-Label Trial; Shares Rise Pre-Bell	10/12/21	MT
Context Therapeutics Closes $31.3 Million Private Placement of Common Shares, Warrants; Shares Up After Hours	06/12/21	MT
Context Therapeutics Q3 Net Loss Widens	02/12/21	MT
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Reports Q3 Loss $-4.00	02/12/21	MT
Health Care Stocks Trailing Thursday Field Higher	02/12/21	MT
Sector Update: Health Care	02/12/21	MT
Top Midday Decliners	02/12/21	MT
Context Therapeutics Expects to Raise $31.3 Million in Private Placement of Common Shares, Warrants	02/12/21	MT
Context Therapeutics Names Jennifer Minai-Azary Chief Financial Officer	01/11/21	MT
Centrexion Therapeutics : Context Therapeutics Closes $28.8 Million IPO	22/10/21	MT

Chart Centrexion Therapeutics Corporation

Duration

Period

Chart Centrexion Therapeutics Corporation

More charts

Company Profile

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	47.96B
IQVIA HOLDINGS INC.	+0.69%	42.45B
LONZA GROUP AG	+44.81%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research